Johnson & Johnson

NYSE:JNJ   11:26:11 AM EDT
167.31
-0.32 (-0.19%)
Products

Janssen Pharmaceutical Says FDA Approved Two New Indications For Xarelto To Help Prevent, Treat Blood Clots In Pediatric Patients

Published: 12/21/2021 04:28 GMT
Johnson & Johnson (JNJ) - :fda Approves Two New Indications for Xarelto® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients.
Janssen-fda Approves Two New Indications for Xarelto® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients.
Janssen- Oral Suspension Formulation is Expected to Become Available in U.S. for Pediatric Patients in Mid-january 2022.